Literature DB >> 16523259

Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, Tsokos M, Quezado M. Pathological findings in a patient with Fabry disease, who died after 2.5 years of enzyme replacement. Virchows Arch. 2005 Nov 29; 1-7.

Juan Politei.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16523259     DOI： 10.1007/s00428-006-0170-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.064


× No keyword cloud information.
  3 in total

Review 1.  Renoprotection by enzyme replacement therapy.

Authors:  Barry M Brenner; Jean-Pierre Grünfeld
Journal:  Curr Opin Nephrol Hypertens       Date:  2004-03       Impact factor: 2.894

2.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors:  C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

3.  Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency.

Authors:  Peter F Bodary; Yuechun Shen; Fernando B Vargas; Xiaoming Bi; Kristen A Ostenso; Shufang Gu; James A Shayman; Daniel T Eitzman
Journal:  Circulation       Date:  2005-01-24       Impact factor: 29.690
  3 in total
  1 in total

1.  Structural and functional changes in peripheral vasculature of Fabry patients.

Authors:  Riikka J Kalliokoski; Kari K Kalliokoski; Maila Penttinen; Ilkka Kantola; Aila Leino; Jorma S Viikari; Olli Simell; Pirjo Nuutila; Olli T Raitakari
Journal:  J Inherit Metab Dis       Date:  2006-08-12       Impact factor: 4.982
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.